LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion
Investegate announcements from Global Blood Therapeutics, Inc, Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease